Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status | Zendy

Nagla Abdel Karim | Zendy; Salma Musaad | Zendy; Ahmad Zarzour | Zendy; Sadanand B. Patil | Zendy; Abdul Rahman Jazieh | Zendy

Open Access

Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status

Author(s) -

Nagla Abdel Karim,

Salma Musaad,

Ahmad Zarzour,

Sadanand B. Patil,

Abdul Rahman Jazieh

Publication year - 2014

Publication title -

clinical medicine insights oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.601

H-Index - 26

ISSN - 1179-5549

DOI - 10.4137/cmo.s15172

Subject(s) - medicine , gefitinib , lung cancer , performance status , hazard ratio , rash , population , nausea , quality of life (healthcare) , gastroenterology , cancer , oncology , surgery , confidence interval , epidermal growth factor receptor , environmental health , nursing

Patients with advanced non-small cell lung cancer (NSCLC) have no curative treatment options; therefore, improving their quality of life (QOL) is an important goal. Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, is a safe oral agent that may be of benefit to a specific population of NSCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research